{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Received Radiation Therapy"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"Transfusions"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"title":"Inpatient Admissions"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20"}]}],"title":"Treatment-Related Outpatient Visits"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}],"title":"Emergency Department Visits"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"title":"Palliative Care Outpatient Visit"}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"To the extent that they are available, HCRU \\[i.e., radiation therapy, transfusions (red blood cells or platelets), inpatient admissions, treatment-related outpatient visits, emergency department visits, palliative care outpatient visits\\] that occurred during BLENREP treatment will be summarized by the percentage and frequency distribution of patients with any occurrence of the respective outcome.","groups":[{"description":"Participants with relapsed and/or refractory multiple myeloma who were treated with Belantamab Mafodotin - blmf (BLENREP) in the DCI Oncology outpatient clinics between August 5, 2020 and November 7, 2023","id":"OG000","title":"Multiple Myeloma/Blenrep Participants"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Between baseline and earliest of end of BLENREP treatment, death, lost to contact or end of study timeframe, up to 40 months.","title":"Healthcare Resource Utilization (HCRU)","type":"SECONDARY","unitOfMeasure":"Participants"}